OOIR: Observatory of International Research

Papers

(The TQCC of Nature Reviews Neurology is 10. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
Serum NfL as an MS biomarker	426
Olfactory network function altered in COVID-19	376
Long-term safety of satralizumab in NMOSD	329
Sodium channelopathy could underlie concussion symptoms	256
Cortical blood flow associated with cognitive decline in REM sleep behaviour disorder	254
Insight into molecular mechanisms of resistance against prion strains	234
Fatty acids might slow ALS progression	221
Promising results for antisense RNA therapy in mouse models of diffuse midline glioma	219
α-Crystallin B autoimmunity and multiple sclerosis	218
Are guidelines a useful tool for improving outcomes in neurology?	203
CNS drug delivery improves chemotherapy	186
Remyelination stops degeneration in MS	176
Inflammasome insight in tauopathies	173
Rapid AQP4-IgG detection in neuromyelitis optica spectrum disorder	167
Twin study probes non-heritable immune aspects of multiple sclerosis	162
High rate of epilepsy in young individuals who died with COVID-19	161
Multiple sclerosis treatment blunts SARS-CoV-2 antibody response	161
Brain stimulation aids walking after spinal injury	157
Deep learning distinguishes tauopathies	157
Microscopic blood–brain barrier permeability in reversible cerebral vasoconstriction syndrome	146
GluA2 modulator targets excitotoxicity in MS	140
Operationalizing the clinical staging scheme in the 2018 NIA–AA research framework	139
α-Synuclein-activated microglia are implicated in PD pathogenesis	121
Deciphering nociplastic pain: clinical features, risk factors and potential mechanisms	118
Multiple sclerosis relapses not associated with mRNA COVID-19 vaccine	116

A promising new therapy for ALS	110
Microglia, spreaders of Aβ seeds	110
Neurogenesis altered in multiple neurodegenerative diseases	110
New blood biomarker of refractory epilepsy	108
Addressing disparities in neurology by identifying gaps in hospital care	108
TNF — a potential therapeutic target for ALS	100
Transmembrane protein interacts with α-synuclein to confer risk of PD	99
APOE4 provokes tau aggregation via inhibition of noradrenaline transport	98
Skin α-synuclein differentiates synucleinopathies	97
A biomarker for mild cognitive impairment	97
Finger-prick blood test for Alzheimer disease	95
Engineered T cells show therapeutic potential for CNS injury	94
BCAS1+ oligodendrocytes aid remyelination in MS	94
Daily step count linked to dementia risk	93
Potassium regulation could be key to healthy brain ageing	91
Prodromal psychiatric symptoms in MS	91
Antisense oligonucleotide shows potential in Charcot–Marie–Tooth disease	87
Charting brain development across the human lifespan	83
Prodromal Parkinson disease — time is brain	82
ALS pathogenesis linked to actin barrier collapse	81
Targeting connexin hemichannels to treat temporal lobe epilepsy	78
Refining oxytocin therapy for autism: context is key	78
Exosomal microRNAs may aid differential diagnosis of movement disorders	77
Tackling the global burden of diabetic neuropathy	75
Aberrant protein networks in Alzheimer disease	73
RAB32 variant is associated with PD susceptibility	70
Lymphatic propagation of α-synuclein	68
Insights into the toxic effects of mutant huntingtin	63
Additive effects of EBV and HHV-6A on MS risk	63
Novel causal genes in Angelman syndrome	63
Getting specific: targeting Fc receptors in myasthenia gravis	62
Genetics of common cerebral small vessel disease	62
AI and protein structure and function in neurological disease: relevance to disease management	60
Non-invasive stimulation for treating cognitive impairment in Alzheimer disease	59
Author Correction: The human connectome in Alzheimer disease — relationship to biomarkers and genetics	57
Reply to: Assessing prospective memory beyond experimental tasks	56
Does antiherpetic antiviral therapy reduce the risk of dementia?	55
Adaptive and maladaptive myelination in health and disease	54
Publisher Correction: Peripheral and central immune system crosstalk in Alzheimer disease — a research prospectus	53
Neurological manifestations of rhino-oculo-cerebral mucormycosis in the COVID-19 era	53
Ventricular enlargement caused by aducanumab	51
John Q. Trojanowski	51
MRI predicts cognitive training effects in multiple sclerosis	50
Genome-wide analysis furthers decoding of Alzheimer disease genetics	50
Publisher Correction: The neuroanatomical–functional paradox in spinal cord injury	49
The murky waters of sex differences in post-stroke cognitive impairment	49
Zavegepant for the acute treatment of migraine: look before leaping	48
Identifying molecular targets in trigeminal nociception	48
Towards the era of biological biomarkers for Parkinson disease	47
Schizophrenia: genetic insights with clinical potential	45

Treating epilepsy in forcibly displaced persons: timely, necessary, affordable	45
AI and deep brain stimulation: what have we learned?	45
Reply to: Questioning the cycad theory of Kii ALS–PDC causation	42
‘On-demand’ gene therapy for epilepsy	40
Headache in people with epilepsy	40
Reply to ‘Cognitive criteria in HIV: greater consensus is needed’	40
Neuropsychology’s race problem does not begin or end with demographically adjusted norms	39
Immune responses influence sex differences in Alzheimer disease	38
Disentangling clinical and biological trajectories of neurodegenerative diseases	38
Author Correction: The complex aetiology of cerebral palsy	37
Author Correction: Neurological care for LGBT+ people	36
Vaccination and immunotherapies in neuroimmunological diseases	36
Addressing disparities in the global epidemiology of stroke	36
Neuroprognostication: a conceptual framework	36
Epstein–Barr virus as a leading cause of multiple sclerosis: mechanisms and implications	35
Non-neuronal cells in amyotrophic lateral sclerosis — from pathogenesis to biomarkers	35
Pathogenetic mechanisms and treatment targets in cerebral malaria	34
Can we learn lessons from the FDA’s approval of aducanumab?	33
Global synergistic actions to improve brain health for human development	32
Diagnosis and management of migraine in ten steps	32
Bruton tyrosine kinase inhibitors for multiple sclerosis	32
Molecular biomarkers for vascular cognitive impairment and dementia	31
Neural cell state shifts and fate loss in ageing and age-related diseases	31
Schizophrenia: from neurochemistry to circuits, symptoms and treatments	31
Alzheimer disease in African American individuals: increased incidence or not enough data?	30
Gaucher disease provides a unique window into Parkinson disease pathogenesis	30
Mechanisms underlying HIV-associated cognitive impairment and emerging therapies for its management	30
Circadian rhythms in neurodegenerative disorders	30
Redefining cerebral palsies as a diverse group of neurodevelopmental disorders with genetic aetiology	30
IDH inhibition in gliomas: from preclinical models to clinical trials	30
Insights into influences on Alzheimer disease blood biomarkers	29
The amyotrophic lateral sclerosis exposome: recent advances and future directions	29
Levosimendan fails to improve respiratory function in amyotrophic lateral sclerosis	28
Nusinersen treatment response markers	28
NODDI reveals brain microstructural changes in multiple sclerosis	27
WNT receptor variant linked to synaptic degeneration	27
Study reveals new ALS risk genes	26
High-frequency spinal cord stimulation alleviates painful diabetic neuropathy	25
Dense-core plaques could be beneficial in AD	25
Microglial optogenetics triggers chronic pain in mice	24
Challenging the psychiatry–neurology divide: the case of autoimmune encephalitis	23
A CSF marker of nusinersen treatment response	23
Early microbiome changes in neurodegenerative disease	23
Neuroinflammation in spinal muscular atrophy	21
Continuous levodopa production by an artificial enzyme	20
Disease-specific modifications of tau protein	19
Spinal muscular atrophy treatment in utero	19
Mechanistic insights into the interaction between epilepsy and sleep	19
Early-onset dementia in autism spectrum disorder	17
Addressing racial inequities in neuropsychological assessment requires international prescriptive standards, not demographically adjusted norms	17
COVID-19 dominates discussions at AAN 2021	16
Implications of research that excludes under-served populations	16
Clinical trials for idiopathic intracranial hypertension: what are we treating?	15
TREM2 mediates phagocytosis in glioblastoma	15
FTD–ALS risk factors converge on the endolysosomal pathway	15
CD11c+ macrophages mediate brain-to-gut α-synuclein trafficking	15
PACAP — an alternative target to CGRP?	15
Exome sequencing identifies risk variants for AD	14
Iron chelator therapy leads to PD worsening	14
Nanoprobe for blood–brain barrier changes	13
Surprise neurovascular dysfunction in frontotemporal dementia	13
Mitochondrial DNA instability in Huntington disease	12
Clocking the age of Parkinson disease onset	12
Imperatives and co-benefits of research into climate change and neurological disease	11
Effects of diet on MS onset and course	11
New mechanistic insights into TDP-43 pathology	11
Neurofilament marks prodrome onset in FTD	11
A new scale to assess gastrointestinal dysfunction in Parkinson disease	11
Altered muscle cholesterol transport in ALS	11
Highlights from AAIC 2023	11
Parkinson disease and air pollution: does what we breathe matter?	10
Genes associated with multiple system atrophy	10
Cell-based therapies for neurological disorders — the bioreactor hypothesis	10
Microglia subset associated with high-grade glioma	10
Why functional neurological disorder is not feigning or malingering	10